Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-29
2000-04-18
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514597, A61K 31495
Patent
active
060515767
ABSTRACT:
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, or ionically linked to one another to form a single workings composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may be administered by itself or in the form of a bioerodible or nonbioerodible substance.
REFERENCES:
patent: 4194581 (1980-03-01), Leong
patent: 4267326 (1981-05-01), Ozaki et al.
patent: 4489065 (1984-12-01), Walton et al.
patent: 4897260 (1990-01-01), Ross et al.
patent: 4910192 (1990-03-01), Avery et al.
patent: 4933324 (1990-06-01), Shashoua
patent: 4975278 (1990-12-01), Senter et al.
patent: 5057301 (1991-10-01), Wilbur et al.
patent: 5104877 (1992-04-01), Boger
patent: 5112835 (1992-05-01), Miyasaka et al.
patent: 5130126 (1992-07-01), Koyama et al.
patent: 5171566 (1992-12-01), Mizushima et al.
patent: 5176907 (1993-01-01), Leong
patent: 5177064 (1993-01-01), Bodor
Chemical Abstracts AN 1989: 454065, Jones et al, 1989.
Kellen et al., Anticancer Research, vol. 8, p. 1373-76 (1988).
Gagliardi et al., Cancer Research, vol. 52, p. 5073-75 (Sep. 15, 1992).
Chemical Abstracts, vol. 117 (8), Abstract No. 76315m. 1992.
Chemical Abstracts, vol. 116 (18), Abstract No. 181046b. 1992.
Collins et al., "Inhibition of Angiogenesis by Suramin", Cancer Research, vol. 52, pp. 5073-5075, Sep. 15, 1992.
Suramin Merck Index, 11th Ed., Merck and Col, Inc., 1989, Abstracts 417 and 8696.
Jones, R. N., "In Vitro Activity of Ro 24-6392, a Novel Ester-Linked Co-Drug Combining Ciprofloxacin and Desacetylcefotaxime", Eur. J. Clin. Microbiol. Infect Dis., vol. 9, 1990, pp. 435-438.
Segawa et al., "Effect of a New Non-steroidal Anti-inflammatory Combination of a Histamine H.sub.2 Antagonist and Indometacin on Gastroduodenal Muscosal Membrane in Rat", Arzneimittel-Forschung Drug Research, 1992, vol. 42, No. 10, pp. 1171-1270.
Jones, Ronald N., "Impact of Changing Pathogens and Antimicrobial Susceptibility Patterns in the Treatment of Serious Infections in Hospitalized Patients", Symposium on Antimicrobial Therapy, The American Journal of Medicine, Jun. 24, 1996, vol. 100, pp. (6A-3S)-(6A-12S).
Jones, R. N., "Isepamicin (SCH 21420, 1-N-HAPA Gentamicin B): Microbiological Characteristics Including Antimicrobial Potency and Spectrum of Activity", Journal of Chemotherapy, vol. 7, pp. 7-16.
Dose et al., "Physiological and Behavioral Effects of Early Embryonic Exposure to Ethanol and Cocaine in the Young Chick", Neurotoxicology and Teratology, 1995, vol. 17, No. 1, pp. 49-55.
Casteels-Josson et al., "Acute Transcriptional Response of the Honeybee Peptide-Antibiotics Gene Repertoire and Required Post-transnational Conversion of the Precursor Structures", The Journal of Biological Chemistry, Nov. 18, 1994, vol. 269, No. 46, pp. 28569-28575.
Knisely et al., "Effects of Carbon Monoxide in Combination With Behaviorally Active Drugs on Fixed-Ration Performance in the Mouse", Neurotoxicology and Teratology, 1989, vol. 11, pp. 447-452.
Jones et al., "In Vitro Activity of Clarithromycin (TE-031, A-67268) and 14OH-Clarithromycin Alone and in Combination against Legionella Species", Eur. J. Clin. Microbiol. Infect. Dis., vol. 9, pp. 846-848.
Jones et al., "In Vitro Activity of Ro 23-9424, Ceftazidime, and Eight Other Newer Beta-Lactams Against 100 Gram-Positive Blood Culture Isolates", Diagnostic Microbiology and Infectious Disease, vol. 12, No. 2, Mar./Apr. 1989, pp. 143-147.
Fuchs et al., "Evaluation of Disk Susceptibility Testing of Cefotaxime/Desacetylcefotaxime", Diagnostic Microbiology and Infectious Disease, vol. 12, No. 1, Jan./Feb. 1989, pp. 81-85.
Jones et al., "Piperacillin/Tazobactam (YTR 830) Combination", Diagnostic Microbiology and Infectious Disease, vol. 12, No. 6, Nov./Dec. 1989, pp. 489-494.
Jones, Ronald N., "Cefotaxime and Desacetylcefotaxime Antimicrobial Interactions", Diagnostic Microbiology and Infectious Disease, vol. 22, No. 1-2, May/Jun. 1995, pp. 19-33.
Jones, Ronald N., "Broth-Disk Elution Tests to Predict the Susceptibility of Anaerobic Bacteria to the Ampicillin-Sulbactam Combination", Diagnostic Microbiology and Infectious Disease, vol. 13, No. 4, Jul./Aug. 1990, 353-355.
Ashton Paul
Crooks Peter Anthony
Cynkowska Grazyna
Cynkowski Tadeusz
Guo Hone
MacMillan Keith D.
University of Kentucky Research Foundation
LandOfFree
Means to achieve sustained release of synergistic drugs by conju does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means to achieve sustained release of synergistic drugs by conju, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means to achieve sustained release of synergistic drugs by conju will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2336580